GVR Report cover Clinical Nutrition For Cancer Care Market Size, Share & Trends Report

Clinical Nutrition For Cancer Care Market Size, Share & Trends Analysis Report By Product (Oral, Nutrition Enteral Feeding Formulas, Parenteral Nutrition), By Stage, By Sales Channel, By Region, And Segment Forecasts, 2024 - 2030

  • Report ID: GVR-4-68040-208-3
  • Number of Pages: 125
  • Format: Electronic (PDF)
  • Historical Range: 2018 - 2023
  • Industry: Healthcare

Market Size & Trends

The global clinical nutrition for cancer care market size was estimated at USD 5.63 billion in 2023 and is expected to grow a compound annual growth rate (CAGR) of 5.04% from 2024 to 2030. The increasing prevalence of cancer and rising awareness about the benefits of medical foods for fast recovery during cancer treatments is expected to fuel the market. According to the American Association for Cancer Research Progress Report 2023, the overall U.S. cancer mortality rates have seen a decline, owing to the steady downfall of mortality rates from breast, colon, rectum, lung, and prostate cancers. The developments in nutritional supplements for cancer care are a byproduct of the innovation in oncology, aiding the overall immunity of patients with cancer.

U.S. Clinical Nutrition for Cancer Care Market size and growth rate, 2024 - 2030

The American Cancer Society states that cancer treatments often result in a wide range of disorders and long-term side effects that impact the overall health and well-being of cancer survivors. These issues include bone, joint, and soft tissue problems caused by chemotherapy, steroid medications, and hormonal therapy; emotional difficulties; increased risk of secondary cancers like myelodysplastic syndrome or acute myelogenous leukemia; persistent fatigue; heart problems; changes in sexual health; dental and oral health issues; digestion problems; vision problems; and cognitive issues affecting memory, learning, and attention. Medical foods specially designed for cancer patients greatly help in offsetting some of the side effects caused by chemotherapy, which in turn will boost the market for clinical nutrition in the coming few years.

Malnutrition, cachexia, and diminished physical function are some side effects of treatments in oncology, which intensify symptoms, weaken the immune system, delay recovery, and adversely affect the effectiveness of treatments. Consequently, many companies intend to tackle these issues through effective nutritional strategies. Addressing these nutritional issues involves personalized interventions by healthcare providers, including nutritional counseling, dietary modifications, and potentially oral nutritional supplements.

The significance of clinical nutrition for cancer patient care assures upwards growth for the market as it improves quality of life and treatment outcomes. Comprehensive survivorship care, involving regular follow-up with healthcare providers specializing in survivorship care, is crucial to address these potential disorders and effectively manage the long-term side effects and complications arising from cancer treatments. With the growing emphasis on personalized treatments for various illnesses, including cancer and cystic fibrosis, the application of clinical nutrition has gained momentum.

Market Concentration & Characteristics

The market is experiencing moderate growth, accelerating steadily. The global clinical nutrition market for cancer care is consolidated and is characterized by a high degree of innovation.

Clinical Nutrition For Cancer Care Market Concentration & Characteristics

Advancements in medical foods for cancer care have been a significant area of focus in research and development, aiming to enhance treatment outcomes and boost the overall quality of life for individuals battling cancer.

Companies in the clinical nutrition for cancer care market have used strategically implemented M&A and partnerships to expand their product offerings and improve market penetration. In January 2024, Danone partnered with digital oncology company Resilience to create a nutrition and oncology module integrated within Resilience's digital oncology solution. This module aims to address cancer-related malnutrition, which impacts approximately 70% of cancer patients.

In the U.S., clinical nutrition is recognized under the FDA’s 1988 Orphan Drugs Act Amendments. In Europe, the European Food Safety Authority recognized clinical nutrition as food for special purposes in 2015. However, in other parts of the world, the regulation for such products is still in progress. Most of the countries follow the Codex Alimentarius standard as the regulatory guidelines are under development. In 2006, the Food and Safety Standard Act was passed in India to regulate nutraceutical, dietary supplements, and functional foods.

Global players are increasing their presence in booming regional markets to propel market growth. For instance, in July 2022, Nestlé Health Science launched China’s first Foods for Special Medical Purpose (FSMP), Oral Impact Su Yi Su, designed for patients with tumor-related conditions and addressed inflammation and compromised immunity in cancer patients.

Product Insights

Oral clinical nutrition dominated the market in 2023, commanding over 44% market share. Orally administered nutrition products address cancer-related malnutrition, which is a result of metabolic dysregulation and anorexia caused by the tumor and its treatment. These products play a crucial role in enhancing the quality of life of cancer patients by preventing malnutrition, reducing complications, and improving clinical outcomes. They are also designed to cater to taste and smell alterations common in patients undergoing systemic antitumor therapy. Moreover, their ease of consumption makes them particularly suitable for patients who can eat but are malnourished or at risk of malnutrition.

The parenteral nutrition segment is anticipated grow at the fastest rate over the forecast period. Parenteral nutrition is crucial in cancer care due to the high malnutrition rates among patients. Malnutrition can lead to muscle loss, reduced treatment response, and lower quality of life. Thus, parenteral nutrition delivers essential nutrients directly into the bloodstream, bypassing the digestive system. This can slow protein breakdown and reverse protein loss in organs, potentially enhancing treatment outcomes.

Stage Insights

Adults led the segment with over 80% of the market revenue share in 2023 and is also estimated to grow the fastest over the forecast period. This is attributable to the widespread occurrence of malnutrition in adult patients with cancer. Clinical nutrition can decelerate protein degradation and counteract organ protein loss, potentially improving treatment results. Moreover, the implementation of clinical nutrition is meticulously evaluated for each patient, considering their unique health circumstances and nutritional needs.

According to the CDC, approximately 58% of cancer cases are found in adults aged 65 years or older. To cater to their nutritional needs, there has been a significant rise in the introduction of new oncology nutrition products, specifically designed to aid patients in combating diseases and managing the after-effects of treatment. Furthermore, nutrition is increasingly being recognized as a vital component of cancer care, with a significant impact on the health and wellbeing of patients, along with a concerted effort towards the co-design of cancer nutrition care pathways. This is expected to propel market growth further.

Sales Channel Insights

Institutional sales led the market revenue with over 40% share in 2023. These institutions include government organizations, hospitals, and research institutes. The increasing prevalence of cancer necessitates enhanced nutritional support, leading to a surge in clinical nutrition sales in hospitals. The recent healthcare reforms have pressured hospitals to deliver cost-efficient, quality care, increasing the demand for clinical nutrition products. In essence, the high demand for clinical nutrition for cancer care, coupled with the expanding influence of hospitals and the complexity of healthcare systems, underscores why hospitals and institutional sales lead in clinical nutrition sales.

Global Clinical Nutrition for Cancer Care Market share and size, 2023

The online sales segment is anticipated to witness fastest growth over the forecast period. Advancements in telemedicine have enabled the global distribution of clinical nutrition products, allowing manufacturers to broaden their market reach and cater to underserved communities. Thus, online sales have surged due to the increasing customer demand for medical foods catering to nutrition-based deficiencies in patients with cancer.

Regional Insights

North America dominated the market with nearly 34% revenue share in 2023 and is anticipated to grow at the fastest CAGR over the forecast period. Diseases such as esophageal cancer, gastric cancer, head & neck cancer, and laryngeal cancer affect oral food intake in patients. The growing prevalence of these diseases is expected to drive the demand for enteral and parenteral nutrition in the region.

Clinical Nutrition for Cancer Care Market Trends, by Region, 2024 - 2030

U.S. Clinical Nutrition For Cancer Care Market Trends

The U.S. clinical nutrition for cancer care market dominated the North American region with approximately 87% revenue share. The nation’s emphasis on research and substantial investment in the development of nutritional alternatives have solidified its market leadership. Moreover, advanced healthcare infrastructure and accommodating reimbursement policies, paired with considerable investments in healthcare from both public and private sectors, have facilitated the expansion of the market in this area.

Europe Clinical Nutrition For Cancer Care Market Trends

Clinical nutrition for cancer care market in Europe was the second-largest regional market in 2023. The  has proposed evidence-based recommendations regarding the organization of food catering, prescriptions and indications of diets, as well as monitoring of food intake at hospitals, rehabilitation centers, and nursing homes. Growing healthcare expenditure in this region is expected to boost technological advancements in the healthcare industry, which is expected to drive the parenteral nutrition market in the region. Moreover, favorable reimbursement polici0065s, increasing government investment in long-term healthcare, and improving healthcare research infrastructure are expected to boost the usage rates of parenteral nutrition in the next seven years.

The Germany clinical nutrition for cancer care market occupied the largest revenue share in Europe and is anticipated to witness over 7% CAGR over the forecast period. Increasing government investment owing to growing public finances, robust institutional framework, and rising competitiveness among various global & domestic players in parenteral nutrition are a few factors responsible for driving the parenteral nutrition market over the forecast period. Germany has several hospitals, pharmaceuticals, and medical device companies contributing to the robust healthcare economy.

Clinical nutrition for cancer care market in the UK occupied the second-largest revenue share in Europe in 2023. The presence of advanced healthcare facilities & research centers and the fact that it is a manufacturing & services economy indicate its well-developed healthcare system. The country has a large proportion of geriatric population and a high prevalence of cancer.

Asia Pacific Clinical Nutrition For Cancer Care Market Trends

The Asia Pacific clinical nutrition for cancer care market is expected to witness lucrative growth from 2024 to 2030, owing to the increasing population, poverty, and low awareness about nutrition. Significant unmet healthcare needs, high out-of-pocket healthcare spending, and the rapidly growing purchasing power to access various technologically advanced healthcare services are expected to boost the market over the forecast period.

The clinical nutrition for cancer care market in China dominated the market revenue share in Asia Pacific in 2023 and is expected to grow at the fastest CAGR over the forecast period. Moreover, globally prominent companies in the market are expanding their manufacturing or marketing initiatives to China, recognizing the opportunity for market growth in the country. For instance, in November 2023, Danone introduced the Fortimel product range—their first medical nutrition product in the adult Foods for Special Medical Purposes (FSMP) category—in response to rising chronic disease and an aging population in China. The Fortimel Compact Protein was specifically developed to address the nutritional needs of patients recovering from surgery or dealing with non-communicable diseases such as cancer.

Japan clinical nutrition for cancer care market registered the second-largest revenue share in 2023 and is anticipated to witness lucrative growth over the forecast period. An increase in government initiatives regarding technological advancements and balancing effective regulatory compliance requirements is expected to encourage the use of preventive care for geriatric, pediatric, and long-term care patients.

Clinical nutrition for cancer care market in India is anticipated to witness the fastest growth during the forecast period. Clinical nutrition is essential in India, mainly aiding diet adoption for patients with cancer care. The expansion of global players in the region, such as Ajanta Pharma Limited; Hexagon Nutrition Limited; Nutricia Limited; RPG Life Sciences has contributed to market growth significantly. Moreover, increasing per capita healthcare expenditure and rising market penetration of these products in India are among the factors expected to fuel market growth in the coming years.

Key Clinical Nutrition For Cancer Care Company Insights

The global clinical nutrition for cancer care market is consolidated, and prominent companies in the market occupy a significant share. To propel market growth, these companies are collaborating with regional players and expanding globally to expand their nutrition offerings. Some key players operating in the global clinical nutrition for cancer care market include Abbott Nutrition; Nestlé Health Science S.A.; Danone Nutricia.; Fresenius Kabi AG; and Mead Johnson & Company, LLC.

Companies in the clinical nutrition for cancer care market are resorting to diverse strategic approaches to sustain growth, including mergers, collaborations, product development, and global and regional expansions.

Key Clinical Nutrition For Cancer Care Companies:

The following are the leading companies in the clinical nutrition for cancer care market. These companies collectively hold the largest market share and dictate industry trends.

  • Abbott Nutrition
  • Pfizer Inc.
  • Bayer AG
  • Nestle Health Science S.A.
  • GlaxoSmithKline plc
  • Baxter International Inc.
  • Otsuka Holdings Co., Ltd.
  • Mead Johnson & Company, LLC
  • Danone Nutricia
  • Victus, Inc.

Recent Developments

  • In January 2023, Nestlé India expanded its Health Science portfolio by launching ThickenUp Clear, a food and beverage thickener for patients with swallowing difficulties, aiding those with dysphagia due to conditions like head and neck cancer, stroke, and Parkinson’s Disease. The product offered a clear solution to help manage swallowing challenges effectively.

  • In March 2021, Kate Farms launched two products covering Medi-Cal insurance for children and adults. The products, Kate Farms Standard 1.4 Vanilla and Plain, and Kate Farms Pediatric Peptide Vanilla Flavor 1.0 are indicated to treat nutrient deficiency in patients with chronic diseases such as allergies, malnutrition in adults, cancer, and gastrointestinal disorders.

  • In September 2020, Baxter International Inc. received FDA approval for new formulations of Clinimix and Clinimix E injections. These formulations help reach patient protein targets more effectively while delivering less fluid and dextrose.

  • In April 2020, Esperer Onco Nutrition launched oral clinical nutrition supplements Es-Fortitude and Es-Invigour which can be consumed orally for the patients who suffered weight loss due to chemotherapy and other cancer treatments.

Clinical Nutrition For Cancer Care Market Report Scope

Report Attribute


Market size value in 2024

USD 5.91 billion

Revenue forecast in 2030

USD 7.95 billion

Growth rate

CAGR of 5.04% from 2024 to 2030

Actual data

2018 - 2023

Forecast period

2024 - 2030

Quantitative units

Revenue in USD billion/million and CAGR from 2024 to 2030

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, trends

Segments covered

Product, stage, sales channel, region

Regional Scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; Australia; Thailand; South Korea; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait

Key companies profiled

Abbott Nutrition; Pfizer Inc.; Bayer AG; Nestle Health Science S.A.; GlaxoSmithKline plc; Baxter International Inc.; Otsuka Holdings Co., Ltd.; Mead Johnson & Company, LLC; Danone Nutricia; Victus, Inc.

Customization scope

Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options


Global Clinical Nutrition For Cancer Care Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and analyzes the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global clinical nutrition for cancer care market report based on product, stage, sales channel, and region:

Global Clinical Nutrition for Cancer Care Market Report Segmentation

  • Product Outlook (Revenue, USD Million, 2018 - 2030)

    • Oral Nutrition

    • Parenteral Nutrition

    • Enteral Feeding Formulas

  • Stage Outlook (Revenue, USD Million, 2018 - 2030)

    • Adult

    • Pediatric

  • Sales Channel Outlook (Revenue, USD Million, 2018 - 2030)

    • Online

    • Retail

    • Institutional Sales

  • Regional Outlook (Revenue, USD Million, 2018 - 2030)

    • North America

      • U.S.

      • Canada

    • Europe

      • UK

      • Germany

      • France

      • Italy

      • Spain

      • Denmark

      • Sweden

      • Norway

    • Asia Pacific

      • Japan

      • China

      • India

      • Australia

      • Thailand

      • South Korea

    • Latin America

      • Brazil

      • Mexico

      • Argentina

    • Middle East and Africa (MEA)

      • South Africa

      • Saudi Arabia

      • UAE

      • Kuwait

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes data points, ranging from trend analyses to estimates and forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now

Certified Icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.